In a newborn, how is the bilirubin‑albumin ratio calculated and what ratio thresholds guide the need for phototherapy, IVIG, albumin infusion, or exchange transfusion?

Bilirubin-Albumin Ratio in Neonatal Hyperbilirubinemia

Direct Answer

The bilirubin-albumin (B/A) ratio is calculated by dividing total serum bilirubin (TSB) in mg/dL by serum albumin in g/dL, but current AAP guidelines do not use B/A ratio thresholds to guide phototherapy or exchange transfusion decisions—treatment is based solely on TSB levels, gestational age, neurotoxicity risk factors, and postnatal age in hours 1.

Calculation Method

The B/A ratio is calculated as:

• B/A ratio = Total Serum Bilirubin (mg/dL) ÷ Serum Albumin (g/dL)

For example: TSB of 15 mg/dL with albumin of 3.0 g/dL = B/A ratio of 5.0

Research demonstrates that B/A ratios correlate strongly with unbound bilirubin levels (r² = 0.93 in preterm infants not receiving phototherapy), making it a useful surrogate marker when direct unbound bilirubin measurements are unavailable 2.

Critical Guideline Position

The 2024 AAP guideline explicitly states that TSB should be used as the definitive diagnostic test to guide ALL interventions 1. The guideline does not incorporate B/A ratio thresholds into treatment algorithms for:

• Phototherapy initiation
• Exchange transfusion decisions
• IVIG administration
• Albumin infusion

This represents a fundamental shift from older approaches that sometimes incorporated B/A ratios into clinical decision-making.

Treatment Thresholds (TSB-Based Only)

Phototherapy

• Determined by hour-specific TSB nomograms based on:
  • Gestational age (≥35 weeks)
  • Postnatal age in hours
  • Presence of neurotoxicity risk factors 1

Exchange Transfusion

• Indicated when TSB reaches exchange transfusion threshold on hour-specific nomograms
• "Escalation of care" zone: TSB within 0-2 mg/dL below exchange threshold 1

Escalation of Care Protocol

When TSB enters the escalation zone 1:

1. Initiate IV hydration immediately
2. Start emergent intensive phototherapy
3. Measure TSB every 2 hours
4. Consult neonatology if TSB continues rising

Albumin and IVIG: Limited Indications

Albumin Infusion

The FDA label indicates albumin may be used "to bind free bilirubin" in neonatal hemolytic disease, with a dose of 1 g/kg given approximately 1 hour prior to exchange transfusion 3. However:

• Recent meta-analysis shows no significant reduction in total bilirubin overall when albumin is given pre-exchange 4
• A modest reduction in phototherapy duration was observed (11.23 hours shorter) 4
• Pre-exchange albumin priming is not superior to saline in non-hemolytic hyperbilirubinemia 5

Clinical recommendation: Albumin administration before exchange transfusion has minimal evidence support and should not be routine practice.

IVIG Administration

The FDA label does not specifically address IVIG dosing for neonatal hemolysis 6. Research evidence is conflicting:

Against routine IVIG use:

• In ABO hemolytic disease at near-exchange levels, one dose of IVIG did not prevent exchange transfusion or reduce phototherapy duration 7
• Another study found no appreciable benefits in moderate-to-severe ABO HDN 8

Supporting selective IVIG use:

• In direct Coombs-positive ABO hemolytic disease with significant hyperbilirubinemia, IVIG (500 mg/kg) reduced exchange transfusion need from 29% to 7% 9
• High-dose IVIG showed 76% reduction in exchange transfusion odds in hemolytic disease 10

Clinical recommendation: IVIG (500 mg/kg to 1 g/kg) may be considered specifically in direct Coombs-positive hemolytic disease with rapidly rising TSB, but not routinely in ABO incompatibility without positive DAT.

Key Clinical Pitfalls

1. Do not use B/A ratio as a treatment trigger—it is not incorporated into current evidence-based guidelines 1

2. Do not rely on transcutaneous bilirubin (TcB) for treatment decisions—always confirm with TSB when TcB is within 3 mg/dL of treatment threshold 1

3. Recognize that B/A ratio correlation with unbound bilirubin deteriorates after phototherapy (r² drops from 0.93 to 0.69) 2

4. Avoid routine albumin priming before exchange transfusion—evidence does not support this practice 5, 4

5. Monitor for rapid TSB rise (≥0.3 mg/dL/hour in first 24 hours or ≥0.2 mg/dL/hour thereafter) as this suggests hemolysis requiring G6PD testing 1

Practical Algorithm

For any jaundiced newborn ≥35 weeks:

1. Measure TSB (not B/A ratio) when clinically indicated
2. Plot TSB on hour-specific nomogram accounting for gestational age and risk factors
3. If TSB ≥ phototherapy threshold: Start intensive phototherapy
4. If TSB within 0-2 mg/dL of exchange threshold: Initiate escalation protocol (IV fluids + intensive phototherapy + 2-hour TSB monitoring)
5. If TSB ≥ exchange threshold: Prepare for exchange transfusion
6. Consider IVIG only if: Direct Coombs-positive hemolytic disease with rapidly rising TSB despite phototherapy

The B/A ratio remains a research tool and correlate of unbound bilirubin 2, but has no role in clinical decision-making under current evidence-based guidelines 1.